However, the design of new CAIs, which show selective inhibition for tumor-associated isoenzymes, hCA IX and XII, and weak affinity for hCA I and II, currently receives great attention in medicinal chemistry research [15,16,17]. This evidence concerns the gene CYP24A1 and neoplasm.